REQUEST FOR PATIENT and CAREGIVER INPUT: Gilead’s EPCLUSA

A Hep C treatment option for ALL genotypes? What do YOU think about this? Hello!  Once again, HepCBC is calling for your input.  BC PharmaCare is reviewing whether to add another Direct Acting-Antiviral (DAA) for hepatitis C to its formulary (list of drugs it will cover) Patient and Caregiver input is requested by BC PharmaCare on Gilead’s combo of sofosbuvir and velpatasvir for Genotypes 1-6 (brand name: Epclusa®).  Gilead’s combo is the first pan-gen

“Miraculous,” new treatment for Hep C

Less than one percent of Albertans suffer from Hepatitis C, but despite that seemingly low number Dr. Mark Swain with the University of Calgary calls the infection, “prevalent.” That measurement comes in at some 40,000 people. Well, as Dr. Swain tells the Alberta Morning News, a new drug that’s just been approved seeks to help end Hep C. Epclusa is a combination of 2 drugs in one pill, with an enviable success rate. Read more...http://www.630ched.co

Hepatitis C cure approved by Health Canada

(July 13, 2016) – Health Canada has approved a drug being touted as a cure for hepatitis C, a disease believed to have infected hundreds of thousands of Canadians, many of whom are unaware they harbour the virus. The drug, sold under the brand name Epclusa, is a once-daily pill taken for 12 weeks that can rid the body of all six strains of hepatitis C, a blood-borne virus that can lead to severe liver damage and liver cancer if left untreated. “This ...

European Commission Grants Marketing Authorization for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C

– Epclusa is the First and Only All-Oral, Single Tablet Regimen for all Genotypes (1-6) of Chronic Hepatitis C Virus Infection and is Gilead’s Third Sofosbuvir-Based Treatment – FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 8, 2016-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission has granted marketing authorization for Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg), the first pan-genotypic, single tablet regimen for the tre

European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C

--Epclusa is Gilead’s Third Sofosbuvir-Based Treatment to Receive a CHMP Positive Opinion for the Treatment of Chronic HCV Infection-- FOSTER CITY, Calif.--(BUSINESS WIRE)--May 27, 2016-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA...